| Type 1 Diabetes Mellitus |
1 |
1 |
| Pancreas Transplantation |
0 |
0.43 |
| Pancreas |
0 |
0.42 |
| NHS |
0 |
0.37 |
| Artificial Pancreas |
0 |
0.35 |
| Child |
0 |
0.33 |
| Insulin Pump |
0 |
0.99 |
| Biosimilars |
0 |
0.25 |
| Blood |
0 |
0.25 |
| Transplantation |
0 |
0.25 |
| Blood Glucose Test |
0 |
0.24 |
| Biologic Therapy |
0 |
0.22 |
| Adolescent Medicine |
0 |
0.17 |
| Clinical Research |
0 |
0.17 |
| Escherichia coli |
0 |
0.17 |
| Insulin Analog |
0 |
0.98 |
| Medical Innovations |
0 |
0.17 |
| Stem Cell Research and Therapy |
0 |
0.17 |
| UK Site Content |
0 |
0.17 |
| COVID-19 |
0 |
0.14 |
| Health Insurance |
0 |
0.12 |
| Hemoglobin A1c |
0 |
0.12 |
| Electronic Health Record (EHR) |
0 |
0.1 |
| Adverse Effects |
0 |
0.08 |
| Allergy |
0 |
0.08 |
| California |
0 |
0.08 |
| Canada |
0 |
0.08 |
| Disease Management |
0 |
0.08 |
| Dorsum |
0 |
0.08 |
| Epidemiology |
0 |
0.08 |
| Europe |
0 |
0.08 |
| Finger |
0 |
0.08 |
| Food and Drug Administration (FDA) |
0 |
0.08 |
| Generics |
0 |
0.08 |
| Genetics |
0 |
0.08 |
| Gland |
0 |
0.08 |
| Grant |
0 |
0.08 |
| Health Care Services |
0 |
0.08 |
| Hemoglobin |
0 |
0.08 |
| Hypoglycemia |
0 |
0.08 |
| Immunocompromise |
0 |
0.08 |
| Immunosuppressive Therapy |
0 |
0.08 |
| Insulin Therapy |
0 |
0.97 |
| Insurance |
0 |
0.08 |
| Liver |
0 |
0.08 |
| Monoclonal Antibody |
0 |
0.08 |
| New York |
0 |
0.08 |
| Pandemic |
0 |
0.08 |
| Physiology |
0 |
0.08 |
| Prisons |
0 |
0.08 |
| Respiratory Tract Infections |
0 |
0.08 |
| Revenue and Practice Management |
0 |
0.08 |
| Salary and Compensation |
0 |
0.08 |
| Severe Acute Respiratory Syndrome |
0 |
0.08 |
| Stress |
0 |
0.08 |
| Viral Infection |
0 |
0.08 |
| Type 2 Diabetes Mellitus |
0 |
0.07 |
| Acute Respiratory Distress Syndrome |
0 |
0.03 |
| Genomic Medicine |
0 |
0.03 |
| Patient Safety |
0 |
0.03 |